MedPath

PFIZER INC.

PFIZER INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Completed
Conditions
Renal Cell Carcinoma
Interventions
First Posted Date
2010-09-28
Last Posted Date
2018-09-17
Lead Sponsor
Pfizer
Target Recruit Count
1022
Registration Number
NCT01210482
Locations
πŸ‡―πŸ‡΅

Kyusyu University Hospital, Fukuoka-shi, Fukuoka PREF, Japan

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Placebo
Other: Best Supportive Care
First Posted Date
2010-09-28
Last Posted Date
2019-01-09
Lead Sponsor
Pfizer
Target Recruit Count
224
Registration Number
NCT01210495
Locations
πŸ‡ΊπŸ‡Έ

Moores UCSD Cancer Center, La Jolla, California, United States

πŸ‡ΊπŸ‡Έ

UCSD Medical Center- La Jolla, La Jolla, California, United States

πŸ‡ΊπŸ‡Έ

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

and more 73 locations

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Phase 3
Terminated
Conditions
Hypertension, Pulmonary
Interventions
First Posted Date
2010-09-28
Last Posted Date
2011-12-14
Lead Sponsor
Pfizer
Target Recruit Count
2
Registration Number
NCT01210443
Locations
πŸ‡―πŸ‡΅

Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Phase 1
Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2010-09-28
Last Posted Date
2011-06-07
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01210404
Locations
πŸ‡ΊπŸ‡Έ

Pfizer Investigational Site, Overland Park, Kansas, United States

Prevenar (PCV-7) Post-Licensure Safety Study In Russia

Completed
Conditions
Healthy Children After Vaccination
Interventions
Other: Non-interventional observational study
First Posted Date
2010-09-23
Last Posted Date
2012-08-31
Lead Sponsor
Pfizer
Target Recruit Count
100
Registration Number
NCT01207583
Locations
πŸ‡·πŸ‡Ί

Russian Academy of Medical Sciences, Moscow, Russian Federation

πŸ‡·πŸ‡Ί

Russian State Medical University, Moscow, Russian Federation

πŸ‡·πŸ‡Ί

Research Institute of Childhood Infections, Saint Petersburg, Russian Federation

and more 1 locations

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Phase 2
Terminated
Conditions
Ischemic Stroke
Interventions
Other: Placebo
First Posted Date
2010-09-23
Last Posted Date
2016-02-19
Lead Sponsor
Pfizer
Target Recruit Count
181
Registration Number
NCT01208233
Locations
πŸ‡ΊπŸ‡Έ

Spain Rehabilitation Center, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Neurostudies, Inc., Port Charlotte, Florida, United States

πŸ‡ΊπŸ‡Έ

Norwood Nursing Center, Huntington, Indiana, United States

and more 67 locations

Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-09-17
Last Posted Date
2010-10-22
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01204112
Locations
πŸ‡ΊπŸ‡Έ

Pfizer Investigational Site, New Haven, Connecticut, United States

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Phase 3
Terminated
Conditions
Hypertension, Pulmonary
Interventions
First Posted Date
2010-09-17
Last Posted Date
2011-12-01
Lead Sponsor
Pfizer
Target Recruit Count
2
Registration Number
NCT01204853
Locations
πŸ‡―πŸ‡΅

Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan

Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Completed
Conditions
Candidiasis
Interventions
First Posted Date
2010-09-15
Last Posted Date
2014-04-16
Lead Sponsor
Pfizer
Target Recruit Count
50
Registration Number
NCT01202253
Locations
πŸ‡¬πŸ‡§

Pfizer Investigational Site, London, United Kingdom

Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-09-15
Last Posted Date
2011-02-17
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT01202240
Locations
πŸ‡§πŸ‡ͺ

Pfizer Investigational Site, Bruxelles, Belgium

Β© Copyright 2025. All Rights Reserved by MedPath